 |
Monoclonal antibodies PM-81 and AML-2-23 |
|---|---|
| Trade Name | |
| Orphan Indication | For the exogenous depletion of CD14 and CD15 positive acute myeloid leukemic bone marrow cells from patients undergoing bone marrow transplantation |
| USA Market Approval | USA |
| USA Designation Date | 1990-03-12 00:00:00 |
| Sponsor | Medarex, Inc.;519 Route 173 West;Bloomsbury, New Jersey, 08804 |
